Answer
The most frequently reported treatment-related adverse effect in European clinical studies of Taptiqom was conjunctival/ocular hyperaemia, affecting approximately 7% of patients, usually mildly, and leading to treatment discontinuation in 1.2%.
Sources for this answer
- Taptiqom 15 micrograms/ml + 5 mg/ml eye drops, solution in single-dose containerSanten UK Limited · emc · SmPC §4.8 Undesirable effects · Version 5Document updated
Sources checked